AstraZeneca, Amgen notch another late-stage win for Tezspire, this time in esophagitis - BioSpace
AstraZeneca, Amgen notch another late-stage win for Tezspire, this time in esophagitis BioSpace
Amgen Company News
Moderna’s $2B offering; AstraZeneca-Amgen and Biokin chalk up Phase 3 wins - Endpoints News
Moderna’s $2B offering; AstraZeneca-Amgen and Biokin chalk up Phase 3 wins Endpoints News
Amgen, AZ’s Tezspire lands phase 3 eosinophilic esophagitis win, turning up heat on Dupixent - Fierce Pharma
Amgen, AZ’s Tezspire lands phase 3 eosinophilic esophagitis win, turning up heat on Dupixent Fierce Pharma
Top Research Reports for Amgen, Thermo Fisher & Pepsi - Yahoo Finance
Top Research Reports for Amgen, Thermo Fisher & Pepsi Yahoo Finance
New data could widen use of AstraZeneca, Amgen immune disease drug - BioPharma Dive
New data could widen use of AstraZeneca, Amgen immune disease drug BioPharma Dive
Amgen’s AMG 691 Phase 1 Trial Targets Key Growth in Asian Markets - TipRanks
Amgen’s AMG 691 Phase 1 Trial Targets Key Growth in Asian Markets TipRanks
Can Amgen Rake In A New Use For Its Asthma Drug, Tezspire? - Investor's Business Daily
Can Amgen Rake In A New Use For Its Asthma Drug, Tezspire? Investor's Business Daily
Amgen Stock Signals Its Confidence. The Market Agrees. - Trefis
Amgen Stock Signals Its Confidence. The Market Agrees. Trefis
Proficio Capital Partners LLC Makes New Investment in Amgen Inc. $AMGN - MarketBeat
Proficio Capital Partners LLC Makes New Investment in Amgen Inc. $AMGN MarketBeat
AstraZeneca, Amgen Drug Moves Closer to Competing With Dupixent in a New Indication - MedCity News
AstraZeneca, Amgen Drug Moves Closer to Competing With Dupixent in a New Indication MedCity News
AstraZeneca-Amgen asthma drug succeeds in late-stage oesophagus disease trial - Reuters
AstraZeneca-Amgen asthma drug succeeds in late-stage oesophagus disease trial Reuters
Amgen-AstraZeneca’s Tezspire nets another Phase III inflammatory disease win - Clinical Trials Arena
Amgen-AstraZeneca’s Tezspire nets another Phase III inflammatory disease win Clinical Trials Arena
Lady Gaga and her fiancé launch a biotech startup - STAT
Lady Gaga and her fiancé launch a biotech startup STAT
Stonebridge Capital Management Inc. Acquires New Stake in Amgen Inc. $AMGN - MarketBeat
Stonebridge Capital Management Inc. Acquires New Stake in Amgen Inc. $AMGN MarketBeat
Pure Financial Advisors LLC Makes New $2.89 Million Investment in Amgen Inc. $AMGN - MarketBeat
Pure Financial Advisors LLC Makes New $2.89 Million Investment in Amgen Inc. $AMGN MarketBeat
Parvin Asset Management LLC Invests $2.04 Million in Amgen Inc. $AMGN - MarketBeat
Parvin Asset Management LLC Invests $2.04 Million in Amgen Inc. $AMGN MarketBeat
Amgen Inc. $AMGN Shares Sold by Strive Financial Group LLC - MarketBeat
Amgen Inc. $AMGN Shares Sold by Strive Financial Group LLC MarketBeat
Perennial Investment Advisors LLC Purchases Shares of 3,096 Amgen Inc. $AMGN - MarketBeat
Perennial Investment Advisors LLC Purchases Shares of 3,096 Amgen Inc. $AMGN MarketBeat
Palogic Value Management L.P. Takes Position in Amgen Inc. $AMGN - MarketBeat
Palogic Value Management L.P. Takes Position in Amgen Inc. $AMGN MarketBeat
PDT Partners LLC Buys New Shares in Amgen Inc. $AMGN - MarketBeat
PDT Partners LLC Buys New Shares in Amgen Inc. $AMGN MarketBeat
Parallax Volatility Advisers L.P. Makes New $1.94 Million Investment in Amgen Inc. $AMGN - MarketBeat
Parallax Volatility Advisers L.P. Makes New $1.94 Million Investment in Amgen Inc. $AMGN MarketBeat
Amgen Inc. $AMGN Shares Purchased by Corient Private Wealth LP - MarketBeat
Amgen Inc. $AMGN Shares Purchased by Corient Private Wealth LP MarketBeat
Amgen/AZ's Tezspire extends TSLP platform to eosinophilic esophagitis with Phase III win - AllSci
Amgen/AZ's Tezspire extends TSLP platform to eosinophilic esophagitis with Phase III win AllSci
Bontempo Ohly Capital Mgmt LLC Invests $3.37 Million in Amgen Inc. $AMGN - MarketBeat
Bontempo Ohly Capital Mgmt LLC Invests $3.37 Million in Amgen Inc. $AMGN MarketBeat
Corient Private Wealth LP Invests $187.40 Million in Amgen Inc. $AMGN - MarketBeat
Corient Private Wealth LP Invests $187.40 Million in Amgen Inc. $AMGN MarketBeat
Highlights from Amgen's 2026 Second Quarter Earnings Report - Amgen
Highlights from Amgen's 2026 Second Quarter Earnings Report Amgen
The Manufacturers Life Insurance Company Has $416.73 Million Stake in Amgen Inc. $AMGN - MarketBeat
The Manufacturers Life Insurance Company Has $416.73 Million Stake in Amgen Inc. $AMGN MarketBeat
Legal & General Group Plc Sells 53,921 Shares of Amgen Inc. $AMGN - MarketBeat
Legal & General Group Plc Sells 53,921 Shares of Amgen Inc. $AMGN MarketBeat
Amgen Inc. $AMGN Stake Raised by L2 Asset Management LLC - MarketBeat
Amgen Inc. $AMGN Stake Raised by L2 Asset Management LLC MarketBeat
Arini Capital Management Ltd Buys Shares of 20,000 Amgen Inc. $AMGN - MarketBeat
Arini Capital Management Ltd Buys Shares of 20,000 Amgen Inc. $AMGN MarketBeat
2,893 Shares in Amgen Inc. $AMGN Acquired by Ausdal Financial Partners Inc. - MarketBeat
2,893 Shares in Amgen Inc. $AMGN Acquired by Ausdal Financial Partners Inc. MarketBeat
Primecap Management Co. CA Reduces Stake in Amgen Inc. $AMGN - MarketBeat
Primecap Management Co. CA Reduces Stake in Amgen Inc. $AMGN MarketBeat
Amgen Inc. $AMGN Shares Acquired by Man Group plc - MarketBeat
Amgen Inc. $AMGN Shares Acquired by Man Group plc MarketBeat
Canada Pension Plan Investment Board Boosts Stock Position in Amgen Inc. $AMGN - MarketBeat
Canada Pension Plan Investment Board Boosts Stock Position in Amgen Inc. $AMGN MarketBeat
893,898 Shares in Amgen Inc. $AMGN Bought by Jupiter Topco LLC - MarketBeat
893,898 Shares in Amgen Inc. $AMGN Bought by Jupiter Topco LLC MarketBeat
2 Reasons to Like AMGN (and 1 Not So Much) - StockStory
2 Reasons to Like AMGN (and 1 Not So Much) StockStory
AstraZeneca-Amgen asthma drug succeeds in late-stage oesophagus disease trial - Euronext Markets: Real-time Stock Market Data | live
AstraZeneca-Amgen asthma drug succeeds in late-stage oesophagus disease trial Euronext Markets: Real-time Stock Market Data | live
Amgen Inc. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
Amgen Inc. stock underperforms Monday when compared to competitors despite daily gains MarketWatch
Amgen Inc. $AMGN Shares Sold by Evolve Private Wealth LLC - MarketBeat
Amgen Inc. $AMGN Shares Sold by Evolve Private Wealth LLC MarketBeat
FTC Warns Patent-Right Acquisitions Cannot Escape Antitrust Review in Amgen Enbrel Case - PYMNTS.com
FTC Warns Patent-Right Acquisitions Cannot Escape Antitrust Review in Amgen Enbrel Case PYMNTS.com